

hearing together with a statement setting forth in detail the facts to be proved, the relevance of those facts to the issues in this proceeding, a description of the evidence which would be adduced, and why such evidence cannot be submitted by affidavit;

(b) Should any party believe that an oral argument is required, that party must submit a request specifying the reasons therefore and why argument by memorandum is inadequate to present the party's case; and

(c) Any request for evidentiary hearing or oral argument shall be filed no later than May 17, 2006;

It is further ordered that notice of this Order to Show Cause be published in the **Federal Register**, and that a copy thereof be served upon each respondent at its last known address;

It is further ordered that all documents submitted by any party of record in this proceeding shall be filed in accordance with Rule 118 of the Commission's Rules of Practice and Procedure, 46 CFR 502.118, and be mailed directly to all parties of record;

Finally, it is ordered that pursuant to the terms of Rule 61 of the Commission's Rules of Practice and Procedure, 46 CFR 502.61, the final decision of the Commission in this proceeding shall be issued by October 31, 2006.

By the Commission.

**Bryant L. VanBrakle**,  
Secretary.

**SCHEDULE A.—LICENSEES IN THE UNITED STATES**

Organization No.	Name
004278 .....	Cambell & Gardiner, Inc.
008727 .....	Ken Lehat & Associates, Inc.
015494 .....	Ocean Transportation Services, LLC.
011405 .....	Interfreight, Inc.
016391 .....	Caribbean American Shipping Corp.
008751 .....	Ford International Forwarding, Inc.
016817 .....	Independence Shipping Lines, Ltd.
017387 .....	S & B International Freight Forwarders, Inc.

[FR Doc. E6-3789 Filed 3-15-06; 8:45 am]

**BILLING CODE 6730-01-P**

**FEDERAL RESERVE SYSTEM**

**Change in Bank Control Notices; Acquisition of Shares of Bank or Bank Holding Companies**

The notificants listed below have applied under the Change in Bank

Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the office of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than March 31, 2006.

**A. Federal Reserve Bank of Atlanta** (Andre Anderson, Vice President) 1000 Peachtree Street, N.E., Atlanta, Georgia 30303:

1. *W.C. Martin, Jr.; Jean Wood Martin; Donald Wayne Sanders; Mary Martin Noland; Donald Martin Sanders; Rebecca Martin Sanders; William Matthew Sanders*, all of Aliceville, Alabama; Alice Susan Martin, Chattanooga, Tennessee, Milton Barrett Noland, Carrollton, Alabama; and Karrie Noland Beasley, Tuscaloosa, Alabama, to retain voting shares of First National Bancshares of Central Alabama, Inc., and thereby indirectly retain voting shares of First National Bank of Central Alabama, both of Aliceville, Alabama.

Board of Governors of the Federal Reserve System, March 13, 2006.

**Robert deV. Frierson**,  
Deputy Secretary of the Board.

[FR Doc. E6-3811 Filed 3-15-06; 8:45 am]

**BILLING CODE 6210-01-S**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Toxicology Program (NTP), NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM); Notice of Availability of a Revised List of Recommended Reference Substances for Validation of In Vitro Estrogen and Androgen Receptor Binding and Transcriptional Activation Assays: Request for Comments and Submission of In Vivo and In Vitro Data**

**AGENCY:** National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH).

**ACTION:** Request for Comments and Submission of Data.

**SUMMARY:** The National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative

Toxicological Methods (NICEATM) announces the availability of an addendum to the report entitled, "Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) Evaluation of *In Vitro* Test Methods for Detecting Potential Endocrine Disruptors: Estrogen Receptor and Androgen Receptor Binding and Transcriptional Activation Assays" [NIH Publication 03-4503]. The addendum describes the rationale for proposed revisions to the original list of recommended reference substances for validation of *in vitro* estrogen receptor (ER) and androgen receptor (AR) binding and transcriptional activation (TA) assays. The original list was made publicly available in June 2003 (**Federal Register**, Vol. 68, No. 106, pp. 33171-33172, June 3, 2003). NICEATM requests public comments on the substances proposed as substitutes for six of the 78 substances in the original list. Data are also requested from *in vitro* and *in vivo* studies evaluating the estrogenic and androgenic activity of the 78 substances in the revised list of reference substances.

**DATES:** Comments and data submissions should be received by May 1, 2006.

**ADDRESSES:** Correspondence should be sent by mail, fax, or e-mail to Dr. William S. Stokes, NICEATM Director, NIEHS, P. O. Box 12233, MD EC-17, Research Triangle Park, NC, 27709, (phone) 919-541-2384, (fax) 919-541-0947, (e-mail) [niceatm@niehs.nih.gov](mailto:niceatm@niehs.nih.gov).

**SUPPLEMENTARY INFORMATION:**

**Background**

In April 2000, the Environmental Protection Agency (EPA) asked ICCVAM to evaluate the validation status of *in vitro* ER and AR binding and TA assays that were proposed as possible components of the EPA Endocrine Disruptor Screening Program Tier 1 screening battery. ICCVAM agreed to evaluate these test methods based on their potential interagency applicability and public health significance. NICEATM, which administers and provides scientific support for ICCVAM, subsequently compiled available data and information on *in vitro* ER and AR binding and TA assays in four draft Background Review Documents (BRDs) (available at <http://iccvam.niehs.nih.gov/methods/endocrine.htm>).

In collaboration with the ICCVAM Endocrine Disruptor Working Group, NICEATM organized an independent scientific evaluation of the validation status of the four types of *in vitro* endocrine disruptor screening test